<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03919578</url>
  </required_header>
  <id_info>
    <org_study_id>Hep B 0218</org_study_id>
    <nct_id>NCT03919578</nct_id>
  </id_info>
  <brief_title>Protectivity and Safety Following Recombinant Hepatitis B Vaccine</brief_title>
  <official_title>Protectivity and Safety Following Recombinant Hepatitis B Vaccine With Different Source of Hepatitis B Bulk Compared to Hepatitis B (Bio Farma) Vaccine in Indonesian Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protectivity and Safety Following Recombinant Hepatitis B Vaccine with different source of
      Hepatitis B bulk compared to Hepatitis B (Bio Farma) vaccine in Indonesian Population
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protectivity and Safety Following Recombinant Hepatitis B Vaccine with different source of
      Hepatitis B bulk compared to Hepatitis B (Bio Farma) vaccine in Indonesian Population.

      Experimental, randomized, double blind, four arm parallel group study, lot to lot consistency
      study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 11, 2019</start_date>
  <completion_date type="Actual">February 28, 2020</completion_date>
  <primary_completion_date type="Actual">January 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Experimental, randomized, double blind, four arm parallel group study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Investigational product was masking with control</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with increasing antibody titer &gt;= 4 times</measure>
    <time_frame>28 days after the last dose immunization</time_frame>
    <description>Percentage of subjects with increasing antibody titer &gt;= 4 times: in all subjects; comparison between investigational product and control and between each lot number of Recombinant Hepatitis B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT)</measure>
    <time_frame>28 days</time_frame>
    <description>GMT in all subjects; comparison of GMT between investigational products and control and comparison of GMT between each lot number of Recombinant Hepatitis B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with transition of seronegative to seropositive</measure>
    <time_frame>after dosing</time_frame>
    <description>Percentage of subjects with transition of seronegative to seropositive: in all subjects; Subjets which get investigational products and control and each lot number of Recombinant Hepatitis B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with at least one immediate reaction</measure>
    <time_frame>30 minutes after each vaccination</time_frame>
    <description>Immediate reaction (local reaction or systemic event)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with at least one of these adverse events</measure>
    <time_frame>within 72 hours, between 72 hours to 28 days after vaccination</time_frame>
    <description>At least one of these adverse events, expected or not</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse event after vaccination</measure>
    <time_frame>28 days</time_frame>
    <description>Serious adverse event occurring from inclusion until 28 days after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison adverse events between Investigational Products (Hepatitis B) and Control</measure>
    <time_frame>28 days</time_frame>
    <description>Adverse events occuring until 28 days after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of adverse events between each lot number of Recombinant Hepatitis B vaccine</measure>
    <time_frame>28 days</time_frame>
    <description>Adverse events occuring until 28 days after vaccination</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">536</enrollment>
  <condition>Immunogenicity</condition>
  <arm_group>
    <arm_group_label>Hep B Batch 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of 1 mL Hepatitis B Batch 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hep B Batch 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of 1 mL Hepatitis B Batch 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hep B Batch 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of 1 mL Hepatitis B Batch 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hep B (Bio Farma)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of 1 mL Hepatitis B (Bio Farma)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Hepatitis B vaccine</intervention_name>
    <description>Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from Serum Institute of India and then formulated and filled at Bio Farma.</description>
    <arm_group_label>Hep B Batch 1</arm_group_label>
    <arm_group_label>Hep B Batch 2</arm_group_label>
    <arm_group_label>Hep B Batch 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Hepatitis B (Bio Farma)</intervention_name>
    <description>Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from The Janssen Vaccine Corp and then formulated and filled at Bio Farma.</description>
    <arm_group_label>Hep B (Bio Farma)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy individu as determined by clinical judgment, including a medical history and
             physical exam which confirms the absence of a current or past disease state considered
             significant by the investigator.

          2. Subjects/parents/guardian(s) have been informed properly regarding the study and
             signed the informed consent form/ informed assent form.

          3. Subject/parents/guardian(s) will commit to comply with the instructions of the
             investigator and the schedule of the trial.

        Exclusion Criteria:

          1. Subject concomitantly enrolled or scheduled to be enrolled in another trial.

          2. Subjects with known history of Hepatitis B contained vaccination in the last 10 years

          3. Evolving severe illness and/or chronic disease and fever (axillary temperature more
             than37.5oC) within the 48 hours preceding enrollment.

          4. Known history of allergy to any component of the vaccines (based on anamnesis)

          5. HBsAg positive

          6. Known history of immunodeficiency disorder (HIV infection, leukemia, lymphoma, or
             malignancy).

          7. History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular
             injection.

          8. Subject who has received in the previous 4 weeks a treatment likely to alter the
             immune response (intravenous immunoglobulins, blood-derived products or corticosteroid
             therapy and other immunosuppresant.

          9. Pregnancy &amp; Lactation (Adult)

         10. Subject already immunized with any vaccine within 4 weeks prior and expects to receive
             other vaccines within 4 weeks following immunization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yetty M Nency, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitas Diponegoro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RSND</name>
      <address>
        <city>Semarang</city>
        <state>Central Java</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 11, 2019</study_first_submitted>
  <study_first_submitted_qc>April 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

